PPAR medicines and human disease: The ABCs of it all

PPAR Research

Volumn , Issue , 2012, Pages

  Apostoli, Anthony J ^a,b   Nicol, Christopher J B ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; 2 [4 [3 [4,5 DIHYDRO 1 (4 METHYLBENZYL) 5 OXO 1H 1,2,4 TRIAZOL 3 YL]PROPYL]PHENOXY] 2 METHYLPROPIONIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ABC TRANSPORTER; ALEGLITAZAR; BEZAFIBRATE; BREAST CANCER RESISTANCE PROTEIN; CERAMIDE; CIGLITAZONE; CLOFIBRATE; FENOFIBRATE; GEMFIBROZIL; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; MURAGLITAZAR; MYCOPHENOLIC ACID; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PIRINIXIC ACID; PRAVASTATIN; PROSTAGLANDIN J2; ROSIGLITAZONE; SIMVASTATIN; TELMISARTAN; TESAGLITAZAR; TROGLITAZONE; UNINDEXED DRUG;

ATHEROSCLEROSIS; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CLINICAL FEATURE; DNA POLYMORPHISM; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; GLUCOSE METABOLISM; HEART INFARCTION; HUMAN; ICHTHYOSIS; INFLAMMATION; LIPID METABOLISM; LONG TERM CARE; MULTIDRUG RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84866148789     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2012/504918     Document Type: Review

References (124)

1. Wind N. S., Holen I., Multidrug resistance in breast cancer: from in vitro models to clinical studies. International Journal of Breast Cancer 2011 2011 12 967419
2. Slot A. J., Molinski S. V., Cole S. P., Mammalian multidrug-resistance proteins (MRPs). Essays in Biochemistry 2011 50 1 179 207
3. Deeley R. G., Westlake C., Cole S. P. C., Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiological Reviews 2006 86 3 849 899 2-s2.0-33745835398 10.1152/physrev.00035.2005 (Pubitemid 44033384)
4. Dean M., Rzhetsky A., Allikmets R., The human ATP-binding cassette (ABC) transporter superfamily. Genome Research 2001 11 7 1156 1166 2-s2.0-0034917716 10.1101/gr.GR-1649R (Pubitemid 32677289)
5. Rees D. C., Johnson E., Lewinson O., ABC transporters: the power to change. Nature Reviews Molecular Cell Biology 2009 10 3 218 227 2-s2.0-60749083913 10.1038/nrm2646
6. Berger J. P., Akiyama T. E., Meinke P. T., PPARs: therapeutic targets for metabolic disease. Trends in Pharmacological Sciences 2005 26 5 244 251 2-s2.0-18044376795 10.1016/j.tips.2005.03.003 (Pubitemid 40603072)
7. Kostadinova R., Wahli W., Michalik L., PPARs in diseases: control mechanisms of inflammation. Current Medicinal Chemistry 2005 12 25 2995 3009 2-s2.0-27944505915 10.2174/092986705774462905 (Pubitemid 41672488)
8. Peters J. M., Shah Y. M., Gonzalez F. J., The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nature Reviews Cancer 2012 12 181 195
9. Montagner A., Rando G., Degueurce G., Leuenberger N., Michalik L., Wahli W., New insights into the role of PPARs. Prostaglandins Leukotrienes and Essential Fatty Acids 2011 85 5 235 243 2-s2.0-79960295133 10.1016/j.plefa.2011. 04.016
10. Wang Y. X., PPARs: diverse regulators in energy metabolism and metabolic diseases. Cell Research 2010 20 2 124 137 2-s2.0-76449100708 10.1038/cr.2010.13
11. Michalik L., Auwerx J., Berger J. P., Chatterjee V. K., Glass C. K., Gonzalez F. J., Grimaldi P. A., Kadowaki T., Lazar M. A., O'Rahilly S., Palmer C. N. A., Plutzky J., Reddy J. K., Spiegelman B. M., Staels B., Wahli W., International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacological Reviews 2006 58 4 726 741 2-s2.0-33751533892 10.1124/pr.58.4.5 (Pubitemid 44833742)
12. Willson T. M., Brown P. J., Sternbach D. D., Henke B. R., The PPARs: from orphan receptors to drug discovery. Journal of Medicinal Chemistry 2000 43 4 527 550 2-s2.0-0033998334 10.1021/jm990554g (Pubitemid 30127149)
13. Shulman A. I., Mangelsdorf D. J., Retinoid X receptor heterodimers in the metabolic syndrome. New England Journal of Medicine 2005 353 6 604 615 2-s2.0-23444431623 10.1056/NEJMra043590 (Pubitemid 41138942)
14. Ricote M., Glass C. K., PPARs and molecular mechanisms of transrepression. Biochimica et Biophysica Acta 2007 1771 8 926 935 2-s2.0-34547603895 10.1016/j.bbalip.2007.02.013 (Pubitemid 47198544)
15. Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou J. P., Staels B., Auwerx J., Laville M., Vidal H., Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor- α in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997 46 8 1319 1327 2-s2.0-0030747895 (Pubitemid 27315281)
16. Issemann I., Green S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990 347 6294 645 650 2-s2.0-0025132245 10.1038/347645a0 (Pubitemid 20356241)
17. Pirat C., Farce A., Lebegue N., Renault N., Furman C., Millet R., Yous S., Speca S., Berthelot P., Desreumaux P., Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. Journal of Medicinal Chemistry 2012 55 94 4027 4061
18. Chawla A., Schwarz E. J., Dimaculangan D. D., Lazar M. A., Peroxisome proliferator-activated receptor (PPAR) γ: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994 135 2 798 800 2-s2.0-0028015713 10.1210/en.135.2.798 (Pubitemid 24241266)
19. Plutzky J., Inflammation in atherosclerosis and diabetes mellitus. Reviews in Endocrine and Metabolic Disorders 2004 5 3 255 259 2-s2.0-3142510687 10.1023/B:REMD.0000032414.17672.5c (Pubitemid 38903583)
20. Ricote M., Huang J., Fajas L., Li A., Welch J., Najib J., Witztum J. L., Auwerx J., Palinski W., Glass C. K., Expression of the peroxisome proliferator-activated receptor γ (PPAR γ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proceedings of the National Academy of Sciences of the United States of America 1998 95 13 7614 7619 2-s2.0-0032560545
21. Spiegelman B. M., PPAR- γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998 47 4 507 514 2-s2.0-0031898610 10.2337/diabetes.47.4.507 (Pubitemid 28160438)
22. Daniel G., Risk of cardiovascular events and all-cause mortality among commercially-insured patients treated with thiazolidinediones. Proceedings of the FDA Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee July 2010
23. Piccinni C., Motola D., Marchesini G., Poluzzi E., Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011 34 6 1369 1371
24. Woodcock J., Sharfstein J. M., Hamburg M., Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. New England Journal of Medicine 2010 363 16 1489 1491 2-s2.0-77957952617 10.1056/NEJMp1010788
25. FDA Drug Safety Communication: Updated drug labels for pioglitazone-containing medicines.
26. Avandia (rosiglitazone): REMSRisk of Cardiovascular Events.
27. Adeghate E., Adem A., Hasan M.Y., Tekes K., Kalasz H., Medicinal chemistry and actions of dual and pan PPAR modulators. The Open Medicinal Chemistry Journal 2011 5 supplement 2 93 98
28. Gottesman M. M., Fojo T., Bates S. E., Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews Cancer 2002 2 1 48 58 2-s2.0-0036364467 (Pubitemid 37328807)
29. Juliano R. L., Ling V., A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochimica et Biophysica Acta 1976 455 1 152 162 2-s2.0-33645830172
30. Ambudkar S. V., Kimchi-Sarfaty C., Sauna Z. E., Gottesman M. M., P-glycoprotein: from genomics to mechanism. Oncogene 2003 22 47 7468 7485 2-s2.0-0344825356 10.1038/sj.onc.1206948 (Pubitemid 37487170)
31. Mechetner E., Kyshtoobayeva A., Zonis S., Kim H., Stroup R., Garcia R., Parker R. J., Fruehauf J. P., Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clinical Cancer Research 1998 4 2 389 398 2-s2.0-0031936939 (Pubitemid 28122754)
32. Atalay C., Gurhan I. D., Irkkan C., Gunduz U., Multidrug resistance in locally advanced breast cancer. Tumor Biology 2006 27 6 309 318 2-s2.0-33750486215 10.1159/000096086 (Pubitemid 44646225)
33. Fletcher J. I., Haber M., Henderson M. J., Norris M. D., ABC transporters in cancer: more than just drug efflux pumps. Nature Reviews Cancer 2010 10 2 147 156 2-s2.0-75149143363 10.1038/nrc2789
34. Cole S. P. C., Bhardwaj G., Gerlach J. H., Mackie J. E., Grant C. E., Almquist K. C., Stewart A. J., Kurz E. U., Duncan A. M. V., Deeley R. G., Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992 258 5088 1650 1654 2-s2.0-0027095653 (Pubitemid 23012438)
35. Szakács G., Paterson J. K., Ludwig J. A., Booth-Genthe C., Gottesman M. M., Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery 2006 5 3 219 234 2-s2.0-33644775686 10.1038/nrd1984 (Pubitemid 43336035)
36. Munoz M., Henderson M., Haber M., Norris M., Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life 2007 59 12 752 757 2-s2.0-39749097290 10.1080/15216540701736285 (Pubitemid 351412076)
37. Maliepaard M., Scheffer G. L., Faneyte I. F., Van Gastelen M. A., Pijnenborg A. C. L. M., Schinkel A. H., Van de Vijver M. J., Scheper R. J., Schellens J. H. M., Subcellular localization and distribution of the Breast Resistance Protein Transporter in normal human tissues. Cancer Research 2001 61 8 3458 3464 2-s2.0-0035870289 (Pubitemid 32695041)
38. Zhou S., Schuetz J. D., Bunting K. D., Colapietro A. M., Sampath J., Morris J. J., Lagutina I., Grosveld G. C., Osawa M., Nakauchi H., Sorrentino B. P., The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature Medicine 2001 7 9 1028 1034 2-s2.0-0034795256 10.1038/nm0901-1028 (Pubitemid 32937383)
39. Miyake K., Mickley L., Litman T., Zhan Z., Robey R., Cristensen B., Brangi M., Greenberger L., Dean M., Fojo T., Bates S. E., Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Research 1999 59 1 8 13 2-s2.0-0032895533 (Pubitemid 29062946)
40. Jonker J. W., Smit J. W., Brinkhuis R. F., Maliepaard M., Beijnen J. H., Schellens J. H. M., Schinkel A. H., Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. Journal of the National Cancer Institute 2000 92 20 1651 1656 2-s2.0-0034684120
41. Kawabata S., Oka M., Shiozawa K., Tsukamoto K., Nakatomi K., Soda H., Fukuda M., Ikegami Y., Sugahara K., Yamada Y., Kamihira S., Doyle L. A., Ross D. D., Kohno S., Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochemical and Biophysical Research Communications 2001 280 5 1216 1223 2-s2.0-0034817098 10.1006/bbrc.2001.4267 (Pubitemid 32917772)
42. Robinson L. J., Roberts W. K., Ling T. T., Lamming D., Sternberg S. S., Roepe P. D., Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochemistry 1997 36 37 11169 11178 2-s2.0-0030964625 10.1021/bi9627830 (Pubitemid 27398436)
43. Smyth M. J., Krasovskis E., Sutton V. R., Johnstone R. W., The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proceedings of the National Academy of Sciences of the United States of America 1998 95 12 7024 7029 2-s2.0-0032499771
44. Tainton K. M., Smyth M. J., Jackson J. T., Tanner J. E., Cerruti L., Jane S. M., Darcy P. K., Johnstone R. W., Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death and Differentiation 2004 11 9 1028 1037 2-s2.0-4544283147 10.1038/sj.cdd.4401440 (Pubitemid 39232362)
45. Miletti-González K. E., Chen S., Muthukumaran N., Saglimbeni G. N., Wu X., Yang J., Apolito K., Shih W. J., Hait W. N., Rodriguez-Rodriguez L., The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Research 2005 65 15 6660 6667 2-s2.0-23044491699 10.1158/0008-5472.CAN-04-3478 (Pubitemid 41060702)
46. Kaye S. B., Reversal of drug resistance in ovarian cancer: where do we go from here? Journal of Clinical Oncology 2008 26 16 2616 2618 2-s2.0-45749138467 10.1200/JCO.2008.16.2123
47. Ogata M., Tsujita M., Hossain M. A., Akita N., Gonzalez F. J., Staels B., Suzuki S., Fukutomi T., Kimura G., Yokoyama S., On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis 2009 205 2 413 419 2-s2.0-67651098675 10.1016/j.atherosclerosis.2009.01.008
48. Ruan X. Z., Moorhead J. F., Fernando R., Wheeler D. C., Powis S. H., Varghese Z., PPAR agonists protect mesangial cells from interleukin 1 β -induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. Journal of the American Society of Nephrology 2003 14 3 593 600 2-s2.0-0037369871 10.1097/01.ASN.0000050414.52908.DA (Pubitemid 36246002)
49. Hossain M. A., Tsujita M., Gonzalez F. J., Yokoyama S., Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes. Journal of Cardiovascular Pharmacology 2008 51 3 258 266 2-s2.0-41349103062 10.1097/FJC.0b013e3181624b22 (Pubitemid 351450604)
50. Jiang Y. J., Lu B., Kim P., Elias P. M., Feingold K. R., Regulation of ABCA1 expression in human keratinocytes and murine epidermis. Journal of Lipid Research 2006 47 10 2248 2258 2-s2.0-33845595443 10.1194/jlr.M600163-JLR200 (Pubitemid 44936135)
51. Arakawa R., Tamehiro N., Nishimaki-Mogami T., Ueda K., Yokoyama S., Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 6 1193 1197 2-s2.0-20144373625 10.1161/01.ATV.0000163844.07815.c4 (Pubitemid 40776608)
52. Chinetti G., Lestavel S., Bocher V., Remaley A. T., Neve B., Torra I. P., Teissier E., Minnich A., Jaye M., Duverger N., Brewer H. B., Fruchart J. C., Clavey V., Staels B., PPAR- α and PPAR- γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Medicine 2001 7 1 53 58 2-s2.0-0035138625 10.1038/83348 (Pubitemid 32095642)
53. Lee J., Hong E. M., Byun H. W., Choi M. H., Jang H. J., Eun C. S., Kae S. H., Choi H. S., The effect of PPAR α and PPAR γ ligands on inflammation and ABCA1 expression in cultured gallbladder epithelial cells. Digestive Diseases and Sciences 2008 53 6 1707 1715 2-s2.0-43049094798 10.1007/s10620-007-0029-5 (Pubitemid 351624415)
54. Kammerer I., Ringseis R., Biemann R., Wen G., Eder K., 13-hydroxy linoleic acid increases expression of the cholesterol transporters ABCA1, ABCG1 and SR-BI and stimulates apoA-I-dependent cholesterol efflux in RAW264.7 macrophages. Lipids in Health and Disease 2011 10, article 222
55. Ringseis R., Wen G., Saal D., Eder K., Conjugated linoleic acid isomers reduce cholesterol accumulation in acetylated LDL-induced mouse RAW264.7 macrophage-derived foam cells. Lipids 2008 43 10 913 923 2-s2.0-51849097150 10.1007/s11745-008-3226-x
56. Ozasa H., Ayaori M., Iizuka M., Terao Y., Uto-Kondo H., Yakushiji E., Takiguchi S., Nakaya K., Hisada T., Uehara Y., Pioglitazone enhances cholesterol efflux from macrophages by increasing ABCA1/ABCG1 expressions via PPARgamma/LXRalpha pathway: findings from in vitro and ex vivo studies. Atherosclerosis 2011 219 1 141 150 10.1016/j.atherosclerosis.2011.07.113
57. Chawla A., Boisvert W. A., Lee C. H., Laffitte B. A., Barak Y., Joseph S. B., Liao D., Nagy L., Edwards P. A., Curtiss L. K., Evans R. M., Tontonoz P., A PPAR γ -LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Molecular Cell 2001 7 1 161 171 2-s2.0-17744376173 10.1016/S1097-2765(01)00164-2 (Pubitemid 32162909)
58. Llaverias G., Lacasa D., Viñals M., Vázquez-Carrera M., Sánchez R. M., Laguna J. C., Alegret M., Reduction of intracellular cholesterol accumulation in THP-1 macrophages by a combination of rosiglitazone and atorvastatin. Biochemical Pharmacology 2004 68 1 155 163 2-s2.0-2942627594 10.1016/j.bcp.2004.03.009 (Pubitemid 38746551)
59. Llaverias G., Rebollo A., Pou J., Vázquez-Carrera M., Sánchez R. M., Laguna J. C., Alegret M., Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. Biochemical Pharmacology 2006 71 5 605 614 2-s2.0-31044433164 10.1016/j.bcp.2005.11.022 (Pubitemid 43121994)
60. Mogilenko D. A., Shavva V. S., Dizhe E. B., Orlov S. V., Perevozchikov A. P., PPAR γ activates ABCA1 gene transcription but reduces the level of ABCA1 protein in HepG2 cells. Biochemical and Biophysical Research Communications 2010 402 3 477 482 2-s2.0-78549284241 10.1016/j.bbrc.2010.10.053
61. Oliver W. R., Shenk J. L., Snaith M. R., Russell C. S., Plunket K. D., Bodkin N. L., Lewis M. C., Winegar D. A., Sznaidman M. L., Lambert M. H., Xu H. E., Sternbach D. D., Kliewer S. A., Hansen B. C., Willson T. M., A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proceedings of the National Academy of Sciences of the United States of America 2001 98 9 5306 5311 2-s2.0-0035942162 10.1073/pnas.091021198 (Pubitemid 32397124)
62. Xu Y., Lai F., Wu Y., Liu Q., Li N., Wei Y., Feng T., Zheng Z., Jiang W., Yu L., Mycophenolic acid induces ATP-binding cassette transporter A1 (ABCA1) expression through the PPARgamma-LXRalpha-ABCA1 pathway. Biochemical and Biophysical Research Communications 2011 414 4 779 782
63. Matsumura T., Kinoshita H., Ishii N., Fukuda K., Motoshima H., Senokuchi T., Taketa K., Kawasaki S., Nishimaki-Mogami T., Kawada T., Nishikawa T., Araki E., Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor- γ in macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology 2011 31 6 1268 1275 2-s2.0-79957455043 10.1161/ATVBAHA.110.222067
64. Sprecher D. L., Massien C., Pearce G., Billin A. N., Perlstein I., Willson T. M., Hassall D. G., Ancellin N., Patterson S. D., Lobe D. C., Johnson T. G., Triglyceride: high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor δ agonist. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 2 359 365 2-s2.0-33846443997 10.1161/01.ATV.0000252790.70572.0c (Pubitemid 46143052)
65. Jiang Y. J., Lu B., Kim P., Paragh G., Schmitz G., Elias P. M., Feingold K. R., PPAR and LXR activators regulate ABCA12 expression in human keratinocytes. Journal of Investigative Dermatology 2008 128 1 104 109 2-s2.0-37049024066 10.1038/sj.jid.5700944 (Pubitemid 350249371)
66. Jiang Y. J., Uchida Y., Lu B., Kim P., Mao C., Akiyama M., Elias P. M., Holleran W. M., Grunfeld C., Feingold K. R., Ceramide stimulates ABCA12 expression via peroxisome proliferator-activated receptor δ in human keratinocytes. Journal of Biological Chemistry 2009 284 28 18942 18952 2-s2.0-67650550792 10.1074/jbc.M109.006973
67. Ehrhardt M., Lindenmaier H., Burhenne J., Haefeli W. E., Weiss J., Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochemical Pharmacology 2004 67 2 285 292 2-s2.0-1642457229 10.1016/j.bcp.2003.09.008 (Pubitemid 38112759)
68. Weiss J., Sauer A., Herzog M., Böger R. H., Haefeli W. E., Benndorf R. A., Interaction of thiazolidinediones (glitazones) with the ATP-Binding cassette transporters P-glycoprotein and breast cancer resistance protein. Pharmacology 2009 84 5 264 270 2-s2.0-70349264523 10.1159/000241734
69. Davies G. F., Juurlink B. H. J., Harkness T. A. A., Troglitazone reverses the multiple drug resistance phenotype in cancer cells. Drug Design, Development and Therapy 2009 3 79 88 2-s2.0-74849116490
70. Chen Q., Zhou J., Jiang C., Chen J., Reversal of P-glycoprotein-mediated multidrug resistance in SGC7901/VCR cells by PPAR γ activation by troglitazone. Journal of Huazhong University of Science and Technology, Medical Science 2010 30 3 326 331 2-s2.0-77956365662 10.1007/s11596-010-0351-6
71. Shoda J., Okada K., Inada Y., Kusama H., Utsunomiya H., Oda K., Yokoi T., Yoshizato K., Suzuki H., Bezafibrate induces multidrug-resistance P-Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice. Hepatology Research 2007 37 7 548 556 2-s2.0-34249908931 10.1111/j.1872-034X.2007.00069.x (Pubitemid 46864251)
72. Shoda J., Inada Y., Tsuji A., Kusama H., Ueda T., Ikegami T., Suzuki H., Sugiyama Y., Cohen D. E., Tanaka N., Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPAR α -mediated redistribution of ABCB4. Journal of Lipid Research 2004 45 10 1813 1825 2-s2.0-16644368576 10.1194/jlr.M400132-JLR200 (Pubitemid 40990873)
73. Kok T., Bloks V. W., Wolters H., Havinga R., Jansen P. L. M., Staels B., Kuipers F., Peroxisome proliferator-activated receptor α (PPAR α)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochemical Journal 2003 369 3 539 547 2-s2.0-0037325403 10.1042/BJ20020981 (Pubitemid 36246237)
74. Marion T. L., Perry C. H., Claire I. R. L. S., Yue W., Brouwer K. L. R., Differential disposition of chenodeoxycholic acid versus taurocholic acid in response to acute troglitazone exposure in rat hepatocytes. Toxicological Sciences 2011 120 2 371 380 2-s2.0-79953071183 10.1093/toxsci/kfr014 kfr014
75. Hoque M. T., Robillard K. R., Bendayan R., Regulation of breast cancer resistant protein (BCRP) by peroxisome proliferator-activated receptor Alpha (PPARalpha) in human brain microvessel endothelial cells. Molecular Pharmacology 2012 81 4 598 609
76. Szatmari I., Vámosi G., Brazda P., Balint B. L., Benko S., Széles L., Jeney V., Özvegy-Laczka C., Szántó A., Barta E., Balla J., Sarkadi B., Nagy L., Peroxisome proliferator-activated receptor γ -regulated ABCG2 expression confers cytoprotection to human dendritic cells. Journal of Biological Chemistry 2006 281 33 23812 23823 2-s2.0-33747640562 10.1074/jbc.M604890200 (Pubitemid 44274157)
77. Kok T., Wolters H., Bloks V. W., Havinga R., Jansen P. L. M., Staels B., Kuipers F., Induction of hepatic ABC transporter expression is part of the PPAr α -mediated fasting response in the mouse. Gastroenterology 2003 124 1 160 171 2-s2.0-0037219280 10.1053/gast.2003.50007 (Pubitemid 36055349)
78. Chianale J., Vollrath V., Wielandt A. M., Amigo L., Rigotti A., Nervi F., Gonzalez S., Andrade L., Pizarro M., Accatino L., Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Biochemical Journal 1996 314 3 781 786 2-s2.0-0029922002 (Pubitemid 26097736)
79. Yoh K., Ishii G., Yokose T., Minegishi Y., Tsuta K., Goto K., Nishiwaki Y., Kodama T., Suga M., Ochiai A., Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clinical Cancer Research 2004 10 5 1691 1697 2-s2.0-12144287061 10.1158/1078-0432.CCR-0937-3 (Pubitemid 38435560)
80. Kool M., De Haas M., Scheffer G. L., Scheper R. J., Van Eijk M. J. T., Juijn J. A., Baas F., Borst P., Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Research 1997 57 16 3537 3547 2-s2.0-0030841332 (Pubitemid 27355505)
81. Van De Ven R., Seheffer G. L., Reurs A. W., Lindenberg J. J., Oerlemans R., Jansen G., Gillet J. P., Glasgow J. N., Pereboev A., Curiel D. T., Scheper R. J., De Gruijl T. D., A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration. Blood 2008 112 6 2353 2359 2-s2.0-55249123453 10.1182/blood-2008-03-147850
82. Moffit J. S., Aleksunes L. M., Maher J. M., Scheffer G. L., Klaassen C. D., Manautou J. E., Induction of hepatic transporters multidrug resistance-associated proteins (Mrp) 3 and 4 by clofibrate is regulated by peroxisome proliferator-activated receptor α Journal of Pharmacology and Experimental Therapeutics 2006 317 2 537 545 2-s2.0-33645865553 10.1124/jpet.105.093765
83. Maher J. M., Cheng X., Slitt A. L., Dieter M. Z., Klaassen C. D., Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metabolism and Disposition 2005 33 7 956 962 2-s2.0-22344433760 10.1124/dmd.105.003798 (Pubitemid 41002777)
84. Maher J. M., Aleksunes L. M., Dieter M. Z., Tanaka Y., Peters J. M., Manautou J. E., Klaassen C. D., Nrf2- and PPAR α -mediated regulation of hepatic mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. Toxicological Sciences 2008 106 2 319 328 2-s2.0-56649113047 10.1093/toxsci/kfn177
85. Hirai T., Fukui Y., Motojima K., PPAR α agonists positively and negatively regulate the expression of several nutrient/drug transporters in mouse small intestine. Biological and Pharmaceutical Bulletin 2007 30 11 2185 2190 2-s2.0-36048940510 10.1248/bpb.30.2185 (Pubitemid 350097033)
86. Salomone S., Pleiotropic effects of glitazones: a double edge sword? Front Pharmacol 2011 2, article 14
87. Tsai M. Y., Ordovas J. M., Li N., Straka R. J., Hanson N. Q., Arends V. L., Arnett D., Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network. Molecular Genetics and Metabolism 2010 100 2 118 122 2-s2.0-77951975010 10.1016/j.ymgme.2010.03.001
88. Knight B. L., Patel D. D., Humphreys S. M., Wiggins D., Gibbons G. F., Inhibition of cholesterol absorption associated with a PPAR α -dependent increase in ABC binding cassette transporter A1 in mice. Journal of Lipid Research 2003 44 11 2049 2058 2-s2.0-0344236149 10.1194/jlr.M300042-JLR200 (Pubitemid 37509620)
89. Johnson D. R., Klaassen C. D., Regulation of rat multidrug resistance protein 2 by classes of prototypical microsomal enzyme inducers that activate distinct transcription pathways. Toxicological Sciences 2002 67 2 182 189 2-s2.0-0036303955 10.1093/toxsci/67.2.182 (Pubitemid 34746471)
90. Tanabe J., Tamasawa N., Yamashita M., Matsuki K., Murakami H., Matsui J., Sugimoto K., Yasujima M., Suda T., Effects of combined PPAR γ and PPAR α agonist therapy on reverse cholesterol transport in the Zucker diabetic fatty rat. Diabetes, Obesity and Metabolism 2008 10 9 772 779 2-s2.0-50249180295 10.1111/j.1463-1326.2007.00810.x
91. Rajkumar T., Yamuna M., Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line. Anti-Cancer Drugs 2008 19 3 257 265 2-s2.0-45549110307 10.1097/CAD.0b013e3282f435b6
92. Schober S. L., Chay T K., Schluns K. S., Lefrancois L., Leiden J. M., Jameson S. C., Expression of the transcription factor lung Kruppel-like factor is regulated by cytokines and correlates with survival memory T cells in vitro and in vivo. Journal of Immunology 1999 163 7 3662 3667 2-s2.0-0344931885 (Pubitemid 29450887)
93. Wang Q., Chen X. P., Hai S., Li G. P., Guan J., Zhang B. X., Zhang W. G., TNF-alpha induced reversal of multidrug resistance in human hepatocellular carcinoma cells. Zhonghua Wai Ke Za Zhi 2007 45 9 602 604 2-s2.0-58149092713
94. Cripe L. D., Uno H., Paietta E. M., Litzow M. R., Ketterling R. P., Bennett J. M., Rowe J. M., Lazarus H. M., Luger S., Tallman M. S., Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood 2010 116 20 4077 4085 2-s2.0-78549238612 10.1182/blood-2010-04-277269
95. Weber C., Noels H., Atherosclerosis: current pathogenesis and therapeutic options. Nature Medicine 2011 17 11 1410 1422
96. Jiang C., Ting A. T., Seed B., PPAR- γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998 391 6662 82 86 2-s2.0-0031888958 10.1038/34184 (Pubitemid 28079219)
97. Ricote M., Li A. C., Willson T. M., Kelly C. J., Glass C. K., The peroxisome proliferator-activated receptor- γ is a negative regulator of macrophage activation. Nature 1998 391 6662 79 82 2-s2.0-0031886864 10.1038/34178 (Pubitemid 28079218)
98. Chinetti G., Griglio S., Antonucci M., Torra I. P., Delerive P., Majd Z., Fruchart J. C., Chapman J., Najib J., Staels B., Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. Journal of Biological Chemistry 1998 273 40 25573 25580 2-s2.0-0032475922 10.1074/jbc.273.40.25573 (Pubitemid 28475776)
99. Tontonoz P., Nagy L., Alvarez J. G. A., Thomazy V. A., Evans R. M., PPAR γ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998 93 2 241 252 2-s2.0-0032540012 10.1016/S0092-8674(00)81575-5 (Pubitemid 28180857)
100. Marx N., Sukhova G., Murphy C., Libby P., Plutzky J., Macrophages in human atheroma contain PPAR γ: differentiation-dependent peroxisomal proliferator-activated receptor γ (PPAR γ) expression and reduction of MMP-9 activity through PPAR γ activation in mononuclear phagocytes in vitro. American Journal of Pathology 1998 153 1 17 23 2-s2.0-0031870652 (Pubitemid 28317502)
101. Chinetti G., Gbaguidi F. G., Griglio S., Mallat Z., Antonucci M., Poulain P., Chapman J., Fruchart J. C., Tedgui A., Najib-Fruchart J., Staels B., CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000 101 20 2411 2417 2-s2.0-0034705071 (Pubitemid 30329133)
102. Lawn R. M., Wade D. P., Garvin M. R., Wang X., Schwartz K., Gordon Porter J., Seilhamer J. J., Vaughan A. M., Oram J. F., The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. Journal of Clinical Investigation 1999 104 8 R25 R31 2-s2.0-0032725185 (Pubitemid 29536327)
103. Wang N., Lan D., Chen W., Matsuura F., Tall A. R., ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proceedings of the National Academy of Sciences of the United States of America 2004 101 26 9774 9779 2-s2.0-3042798281 10.1073/pnas. 0403506101 (Pubitemid 38869312)
104. Costet P., Luo Y., Wang N., Tall A. R., Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. Journal of Biological Chemistry 2000 275 36 28240 28245 2-s2.0-0034623288 10.1074/jbc.M003337200
105. Tobin K. A. R., Steineger H. H., Albert S., Spydevold O., Auwerx J., Gustafsson J. Å., Nebb H. I., Cross-talk between fatty acid and cholesterol metabolism mediated by liver X receptor- α Molecular Endocrinology 2000 14 5 741 752 2-s2.0-0034453225 10.1210/me.14.5.741 (Pubitemid 32266072)
106. Akiyama T. E., Sakai S., Lambert G., Nicol C. J., Matsusue K., Pimprale S., Lee Y. H., Ricote M., Glass C. K., Brewer H. B., Gonzalez F. J., Conditional disruption of the peroxisome proliferator-activated receptor γ gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Molecular and Cellular Biology 2002 22 8 2607 2619 2-s2.0-0036205326 10.1128/MCB.22.8.2607-2619.2002 (Pubitemid 34262983)
107. Malur A., Baker A. D., McCoy A. J., Wells G., Barna B. P., Kavuru M. S., Malur A. G., Thomassen M. J., Restoration of PPAR γ reverses lipid accumulation in alveolar macrophages of GM-CSF knockout mice. American Journal of Physiology 2011 300 1 L73 L80 2-s2.0-78650661677 10.1152/ajplung.00128.2010
108. Fielding C. J., Fielding P. E., Molecular physiology of reverse cholesterol transport. Journal of Lipid Research 1995 36 2 211 228 2-s2.0-0028887870
109. Tall A. R., Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. Journal of Internal Medicine 2008 263 3 256 273 2-s2.0-38849114338 10.1111/j.1365-2796. 2007.01898.x (Pubitemid 351207349)
110. Brewer H. B., High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2004 24 3 387 391 2-s2.0-1542313955 10.1161/01.ATV.0000121505.88326.d2 (Pubitemid 38326126)
111. Rust S., Rosier M., Funke H., Real J., Amoura Z., Piette J. C., Deleuze J. F., Brewer H. B., Duverger N., Denèfle P., Assmann G., Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nature Genetics 1999 22 4 352 355 2-s2.0-0032813660 10.1038/11921 (Pubitemid 29369525)
112. Price M. J., Shah P. K., New strategies in managing and preventing atherosclerosis: focus on HDL. Reviews in Cardiovascular Medicine 2002 3 3 129 137 2-s2.0-0036619331
113. van den Bosch H. M., Bünger M., de Groot P. J., van der Meijde J., Hooiveld G. J. E. J., Müller M., Gene expression of transporters and phase I/II metabolic enzymes in murine small intestine during fasting. BMC Genomics 2007 8, article 267 2-s2.0-34548506266 10.1186/1471-2164-8-267 (Pubitemid 47377699)
114. Barter P. J., Rye K. A., Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 1 39 46 2-s2.0-37549041988 10.1161/ATVBAHA.107.148817
115. Keech A., Simes R. J., Barter P., Best J., Scott R., Taskinen M. R., Forder P., Pillai A., Davis T., Glasziou P., Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet 2005 366 9500 1849 1861
116. Robins S. J., Collins D., Wittes J. T., Papademetriou V., Deedwania P. C., Schaefer E. J., McNamara J. R., Kashyap M. L., Hershman J. M., Wexler L. F., Rubins H. B., Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial. Journal of the American Medical Association 2001 285 12 1585 1591 2-s2.0-0035962077 (Pubitemid 32240250)
117. Jandeleit-Dahm K. A. M., Calkin A., Tikellis C., Thomas M., Direct antiatherosclerotic effects of PPAR agonists. Current Opinion in Lipidology 2009 20 1 24 29 2-s2.0-58849141318 10.1097/MOL.0b013e32831f1b18
118. Home P. D., Pocock S. J., Beck-Nielsen H., Curtis P. S., Gomis R.,
119. Schmuth M., Gruber R., Elias P. M., Williams M. L., Ichthyosis update: towards a function-driven model of pathogenesis of the disorders of cornification and the role of corneocyte proteins in these disorders. Advances in Dermatology 2007 23 231 256 2-s2.0-36048949627 10.1016/j.yadr.2007.07.011
120. Akiyama M., Sugiyama-Nakagiri Y., Sakai K., McMillan J. R., Goto M., Arita K., Tsuji-Abe Y., Tabata N., Matsuoka K., Sasaki R., Sawamura D., Shimizu H., Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer. Journal of Clinical Investigation 2005 115 7 1777 1784 2-s2.0-22144437692 10.1172/JCI24834 (Pubitemid 40979716)
121. Kelsell D. P., Norgett E. E., Unsworth H., Teh M. T., Cullup T., Mein C. A., Dopping-Hepenstal P. J., Dale B. A., Tadini G., Fleckman P., Stephens K. G., Sybert V. P., Mallory S. B., North B. V., Witt D. R., Sprecher E., Taylor A. E. M., Ilchyshyn A., Kennedy C. T., Goodyear H., Moss C., Paige D., Harper J. I., Young B. D., Leigh I. M., Eady R. A. J., O'Toole E. A., Mutations in ABCA12 underlie the severe congenital skin disease harlequin ichthyosis. American Journal of Human Genetics 2005 76 5 794 803 2-s2.0-20244379129 10.1086/429844 (Pubitemid 40563101)
122. Akiyama M., Pathomechanisms of harlequin ichthyosis and ABCA transporters in human diseases. Archives of Dermatology 2006 142 7 914 918 2-s2.0-33746097414 10.1001/archderm.142.7.914 (Pubitemid 44079793)
123. Man M. Q., Choi E. H., Schmuth M., Crumrine D., Uchida Y., Elias P. M., Holleran W. M., Feingold K. R., Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing. Journal of Investigative Dermatology 2006 126 2 386 392 2-s2.0-33644642167 10.1038/sj.jid.5700046 (Pubitemid 43323174)
124. Schurer N. Y., Elias P. M., The biochemistry and function of stratum corneum lipids. Advances in lipid research 1991 24 27 56 2-s2.0-0026279967